Your session is about to expire
← Back to Search
Unlicensed Cord Blood Transplant for Blood/Immune System Disorders
Study Summary
This trial will study the safety of using cord blood stem cells in patients with conditions that affect the blood or immune system.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently receiving treatment with licensed cord blood products.I am receiving a cord blood treatment that involves special processing.I have a blood disorder that is inherited, acquired, or caused by treatment.My age or gender does not limit my participation.My cord blood transplant uses a product made by the NCBP.My age or gender does not limit my participation.
- Group 1: unlicensed CBU
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants can join this research program?
"Correct. Data found on clinicaltrials.gov indicates that this research project is actively recruiting participants, which commenced being posted on February 1st 2012 and was recently modified on April 19th 2022. A total of 9999 patients are being sought from 67 distinct medical facilities."
Is this research endeavor currently accessible to participants?
"Current information posted to clinicaltrials.gov shows that this research project is recruiting participants. Its first post was on February 1st 2012 and the details were most recently updated April 19th 2022."
What risks could potentially accompany the unauthorized use of CBU?
"Our team at Power has assigned unlicensed CBU a score of 2, as the drug is currently being tested in Phase 2 trials and thus there are some safety data but no efficacy evidence."
Are there many venues conducting this research endeavor in North America?
"Participating in this medical trial is possible for those near many different locations, such as the Florida Hospital, Florida Center for Cellular Therapy based in Orlando fl, St. Louis University Hospital located in Saint Louis MO, and Northwestern Memorial Hospital in Chicago il."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger